Realize: A Trial of Single Dose Corifollitropin Alfa's Ability to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI (38833)(P05788)

Sponsor

Organon and Co (Industry)

Overall Status

Completed

CT.gov ID

NCT00702351

Collaborator

(none)

Enrollment

Arms

Actual Duration (Months)

Study Details

Study Description

Brief Summary

To evaluate the induction of multiple follicular growth after single dose administration of 100 μg or 150 μg Org 36286 in a long protocol of GnRH agonist.

Condition or Disease	Intervention/Treatment	Phase
In Vitro Fertilization	Drug: Org 36286 (corifollitropin alfa)	Phase 2

Detailed Description

In this trial, all subjects were (pre)treated daily with subcutaneous triptorelin, a GnRH agonist which is known to provide profound suppression of endogenous LH and FSH. It was evaluated whether these down-regulated subjects show an appropriate ovarian response to 100 μg or 150 μg Org 36286 during the first week of stimulation. To evaluate this, follicular growth was measured by USS, and serum inhibin-B and E2 levels were assessed.

Study Design

Study Type:

Interventional

Actual Enrollment :

50 participants

Allocation:

Non-Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase II, Uncontrolled Pilot Trial to Evaluate That a Single Dose of 100 μg or 150 μg Org 36286 (Corifollitropin Alfa) is Able to Induce Multiple Follicular Growth During the First Week of Controlled Ovarian Stimulation for IVF or ICSI Using a Long Protocol of GnRH Agonist (Study 38833)

Actual Study Start Date :

Dec 9, 2005

Actual Primary Completion Date :

Mar 26, 2007

Actual Study Completion Date :

Jul 11, 2007

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm 1 150 µg Org 36286 (corifollitropin alfa)	Drug: Org 36286 (corifollitropin alfa) A single dose of Org 36286 will be administered after down-regulation has been confirmed (E2 below 50 ng/L and P below 1.48 μg/L). The first group comprising subjects weighing >= 50 kg will receive a dose of 150 μg Org 36286 (150 μg dose group). The second group comprising subjects weighing <= 60 kg will receive a dose of 100 μg Org 36286 (100 μg dose group). Other Names: corifollitropin alfa
Experimental: Arm 2 100 µg Org 36286 (corifollitropin alfa)	Drug: Org 36286 (corifollitropin alfa) A single dose of Org 36286 will be administered after down-regulation has been confirmed (E2 below 50 ng/L and P below 1.48 μg/L). The first group comprising subjects weighing >= 50 kg will receive a dose of 150 μg Org 36286 (150 μg dose group). The second group comprising subjects weighing <= 60 kg will receive a dose of 100 μg Org 36286 (100 μg dose group). Other Names: corifollitropin alfa

Arm

Intervention/Treatment

Experimental: Arm 1

150 µg Org 36286 (corifollitropin alfa)

Drug: Org 36286 (corifollitropin alfa)

A single dose of Org 36286 will be administered after down-regulation has been confirmed (E2 below 50 ng/L and P below 1.48 μg/L). The first group comprising subjects weighing >= 50 kg will receive a dose of 150 μg Org 36286 (150 μg dose group). The second group comprising subjects weighing <= 60 kg will receive a dose of 100 μg Org 36286 (100 μg dose group).

Other Names:

corifollitropin alfa

Experimental: Arm 2

100 µg Org 36286 (corifollitropin alfa)

Drug: Org 36286 (corifollitropin alfa)

Other Names:

corifollitropin alfa

Outcome Measures

Primary Outcome Measures

serum inhibin-B levels; follicle number and follicle size distribution [One cycle]

Secondary Outcome Measures

Amount of recFSH needed from Stimulation Day 8 onwards to the Day of hCG; Endocrinological parameters (FSH, LH, E2, P); Number and quality of oocytes retrieved [One cycle]
Number of fertilized oocytes; Fertilization rate; Number and quality of embryos; Implantation rate; Miscarriage rate; Clinical outcome [One cycle]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 39 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Females of couples with an indication for controlled ovarian stimulation (COS) and IVF or ICSI that have had at least one previous COS cycle with proven normal ovarian response;
=18 and <= 39 years of age at the time of signing informed consent;
1. First group: Body weight >= 50 kg and BMI >= 18 and <= 29 kg/m^{2; b. Second group:
  Body weight <= 60 kg and BMI <= 29 kg/m}2;
Normal menstrual cycle length: 24-35 days;
Ejaculatory sperm (use of donated and/or cryopreserved sperm is allowed);
Normal routine diagnostic hysteroscopy and endometrial biopsy;
Willing and able to sign informed consent.

Exclusion Criteria:

History of or any current (treated) endocrine abnormality;
History of ovarian hyper-response1 or history of ovarian hyperstimulation

syndrome (OHSS);

History of or current polycystic ovary syndrome (PCOS);
A basal antral follicle count > 20 (size < 11 mm, both ovaries combined) on USS during the early follicular phase (menstrual cycle day 2-5);
Less than 2 ovaries or any other ovarian abnormality;
Presence of unilateral or bilateral hydrosalpinx (visible on USS);
Presence of unilateral or bilateral endometriomas (>10 mm; visible on USS);
More than three unsuccessful COS cycles since the last established ongoing

pregnancy (if applicable);

History of non- or low ovarian response to FSH/hMG treatment;
FSH or LH > 12 IU/L as measured by the local laboratory (sample taken during the early follicular phase: menstrual cycle day 2-5);
Any clinically relevant abnormal laboratory value based on a sample taken during the screening phase;
Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts) or GnRH analogues (e.g. hypersensitivity, pregnancy/lactation);
Recent history of or current epilepsy, diabetes or cardiovascular, gastro-intestinal, hepatic, renal or pulmonary disease;
History or presence of alcohol or drug abuse within 12 months prior to signing informed consent;
Previous use of Org 36286;
Use of hormonal preparations within 1 month prior to screening;
Administration of investigational drugs within three months prior to signing